Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Formoterol (6mcg) + Fluticasone Propionate (250mcg)
Therapeutic Category
Anti-Inflammatories, Antispasmodic, Asthma, General and OTC medicines, Pulmonary, Respiratory
Dosage Form
Inhaler
Packaging Type
Metered Dose with Carton and Leaflet
Packaging
120
Price
₹848/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Flutialfa F 250 Inhaler is a combination medication that contains Formoterol (6mcg), a long-acting beta-agonist (LABA), and Fluticasone Propionate (250mcg), a potent corticosteroid. This inhaler is specifically designed for the management of respiratory conditions like asthma and chronic obstructive pulmonary disease (COPD). Formoterol works by relaxing the muscles of the airways, allowing them to open up, which helps improve airflow to the lungs. Fluticasone Propionate reduces inflammation within the airways, preventing the occurrence of asthma attacks or exacerbations in COPD patients.
The combination of these two medications in Flutialfa F 250 Inhaler ensures both long-term bronchodilation and anti-inflammatory effects, providing a comprehensive treatment for patients with asthma and COPD. This inhaler is used as a maintenance therapy to control symptoms, reduce the frequency of exacerbations, and improve overall lung function. It is not intended for immediate relief of acute asthma attacks or COPD flare-ups.
Common side effects include headache, throat irritation, hoarseness, and tremors. Rare but serious side effects may include oral candidiasis (thrush), heart palpitations, or signs of an allergic reaction (rash, swelling).
Flutialfa F 250 Inhaler is indicated for: Asthma: Maintenance treatment for asthma in adults and children (over 12 years) to prevent symptoms and improve lung function. Chronic obstructive pulmonary disease (COPD): Used to reduce exacerbations and manage chronic symptoms of COPD.
This inhaler is for maintenance therapy only and should not be used to relieve acute symptoms. Rinse your mouth after each use to prevent oral thrush. If symptoms persist or worsen, consult your healthcare provider immediately.
Store Flutialfa F 250 Inhaler in a cool, dry place at room temperature (between 15°C to 30°C). Keep the inhaler away from direct sunlight and moisture. Do not refrigerate or freeze the inhaler. Keep it out of the reach of children.
Composition : Formoterol (6mcg) + Budesonide (400mcg) Inhaler
Composition : Salmeterol (50mcg) + Fluticasone Propionate (500 mcg)
Composition : Formoterol (6mcg) + Budesonide (200mcg) Inhaler
Composition : Mometasone (50mcg)
Composition : Fluticasone Furoate (50mcg)
Composition : Fluticasone Furoate (27.5mcg)
Composition : Fluticasone Furoate (27.5mcg) + Azelastine (140mcg)
Composition : Formoterol (12mcg) + Tiotropium (18mcg)
Composition : Levosalbutamol (50mcg) + Ipratropium (20mcg)
Composition : Tiotropium (9mcg)
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
Formoterol 6mcg + Fluticasone Propionate 250mcg Inhaler has strong demand in the respiratory, pulmonology, and chronic disease management segment, making it a valuable product for medical distributors, wholesalers, and pharma franchise partners focusing on asthma and COPD care portfolios.
Medical distributors and agencies can benefit from consistent demand for long-term respiratory disease management under medical supervision. Formoterol 6mcg is a long-acting beta-2 agonist (LABA) that helps relax airway muscles and improve airflow Fluticasone Propionate 250mcg is an inhaled corticosteroid that helps reduce airway inflammation and prevent respiratory symptoms Commonly prescribed for bronchial asthma, chronic obstructive pulmonary disease (COPD), recurrent wheezing, and chronic inflammatory airway diseases Provides dual-action therapy through bronchodilation and inflammation control for better respiratory outcomes Widely prescribed by pulmonologists, chest physicians, and general practitioners This strengthens a comprehensive respiratory and chronic care portfolio.
Yes, Cafoli LifeCare Pvt Ltd offers PCD pharma franchise opportunities for Formoterol 6mcg + Fluticasone Propionate 250mcg Inhaler with promotional support, monopoly rights, attractive packaging, and competitive pricing for distributors and wholesalers.
Wholesalers and medical agencies benefit from strong chronic therapy demand, repeat monthly prescriptions, increasing respiratory disease management needs, reliable supply chain support, and attractive margins in the inhalation therapy segment.
Interested distributors, stockists, and wholesalers can contact Cafoli LifeCare Pvt Ltd to explore PCD pharma franchise opportunities, discuss pricing and business terms, obtain monopoly territory rights, and benefit from comprehensive marketing support, quality pharmaceutical products, and a dependable supply chain to grow their business successfully.